Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Life Science

• Publication date

  2015-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lfs.2015.08.016PMID 26321528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.

  2014cited by this paper
• Elagolix Treatment for Endometriosis-Associated Pain

  2014cited by this paper
• Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.

  2011cited by this paper
• Degarelix for prostate cancer

  2009cited by this paper
• Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.

  2008cited by this paper
• Regression of endometrial explants in a rat model of endometriosis treated with melatonin.

  2008cited by this paper
• Gonadotropin-releasing hormone and the control of gonadotrope function.

  2005cited by this paper
• Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

  2005cited by this paper
• Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis

  2004cited by this paper
• Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.

  2003cited by this paper
• The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.

  2003cited by this paper
• The nature of FSH induction by GnRH.

  2002cited by this paper
• Conventional Medical Therapies for Endometriosis

  2002cited by this paper
• Gonadotropin-releasing-hormone-receptor antagonists.

  2001cited by this paper
• Applications for GnRH antagonists.

  2001cited by this paper
• Dynamic aspects of endometriosis in a mouse model through analysis of implantation and progression

  2000cited by this paper
• ACOG issues recommendations for the management of endometriosis. American College of Obstetricians and Gynecologists.

  2000cited by this paper
• Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency.

  1999cited by this paper
• Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets.

  1998cited by this paper
• Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets.

  1998cited by this paper
• Effect of restraint stress on food intake and body weight is determined by time of day.

  1997cited by this paper
• Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis.

  1997cited by this paper
• GnRH agonists and uterine leiomyomas.

  1996cited by this paper
• The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis.

  1995cited by this paper
• Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis.

  1995cited by this paper
• The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.

  1994cited by this paper
• The use of gonadotrophin releasing-hormone analogues (GnRHa), in in-vitro fertilization: some clinical and experimental investigations of a direct effect on the human ovary.

  1992cited by this paper
• Hormone treatment of endometriosis: the estrogen threshold hypothesis.

  1992cited by this paper
• Overview of osteoporosis.

  1991cited by this paper
• The rat as an animal model for endometriosis to examine recurrence of ectopic endometrial tissue after regression.

  1990cited by this paper
• Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis.

  1990cited by this paper
• Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist.

  1988cited by this paper
• Short- and long-term effects of ovariectomy on food intake, body weight, carcass composition, and brown adipose tissue in rats.

  1987cited by this paper
• The molecular basis of gonadotropin-releasing hormone (GnRH) action in the pituitary gonadotrope.

  1987cited by this paper
• Studies on the surgical induction of endometriosis in the rat.

  1985cited by this paper
• Effects of stress on the gonadal function

  1984cited by this paper
• Medical hypophysectomy: I. Dose-response using a gonadotropin-releasing hormone antagonist.

  1984cited by this paper
• Effect of GnRH antagonist, [Ac-delta 3Pro1, pFDPhe2, DTrp3,6] GnRH, on pulsatile gonadotrop in secretion in the castrate male primate.

  1983cited by this paper
• The effects of acute stress on the secretion of LH, FSH, prolactin and GH in the normal male rat, with comments on their statistical evaluation.

  1974cited by this paper
• Changes in serum levels of gonadotropins and testosterone in the male rat in response to fasting, surgery and ether

  1974cited by this paper

• Neuroendocrine–Immune Axis in Endometriosis: A Review on How the Nervous System Goes Beyond Pain Perception

  2025cites this paper
• Gonadotrophin-releasing hormone receptors in GtoPdb v.2025.3

  2025cites this paper
• From Mice to Primates: Assessing Hormone-Based Endometriosis Models for Preclinical and Therapeutic Insights

  2025cites this paper
• Cryo-EM structures of GnRHR: Foundations for next-generation therapeutics

  2025cites this paper
• Experimental and new investigational drugs for the treatment of uterine fibroids

  2024influential citation
• Gonadotrophin-releasing hormone receptors in GtoPdb v.2023.1

  2023cites this paper
• Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids

  2022cites this paper
• Pharmacological characterization of linzagolix, a novel, orally active, non‐peptide antagonist of gonadotropin‐releasing hormone receptors

  2022cites this paper
• Gonadotrophin-releasing hormone receptors in GtoPdb v.2021.3

  2021cites this paper
• Endometriosis related sex steroid hormones, hypothalamic pituitary gonadal axis hormones and related animal modeling: A comprehensive review of published articles and endometriosis induction methods from 2010 to 2021 with scoring based approach

  2021cites this paper
• Uterine myoma: new and perspective options for medicinal treatment

  2020cites this paper
• First-in-human, double-blind, randomized controlled trial of an oral dose of GnRH antagonist, TU2670 in healthy women.

  2020cites this paper
• Uterine fibroids: an update on current and emerging medical treatment options

  2019cites this paper
• Gonadotrophin-releasing hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• The GnRH analogues affect novel neuropeptide SMIM20/phoenixin and GPR173 receptor expressions in the female rat hypothalamic–pituitary–gonadal (HPG) axis

  2019cites this paper
• Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  2018cites this paper
• Investigational Medical Therapies for Endometriosis: Current Data and Future Trends

  2017cites this paper
• Recent Development of Non-Peptide GnRH Antagonists

  2017influential citation
• Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist.

  2016cites this paper